Arrowhead Pharmaceuticals files IND for pivotal phase 2/3 study of ARO-AAT
Arrowhead Pharma announced it has submitted an IND to the FDA for an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic. March 18, 2019